Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry
Research output: Contribution to journal › Article
Standard
Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. / Farge, D; Passweg, J; van Laar, JM; Marjanovic, Z; Besenthal, C; Finke, J; Peter, HH; Breedveld, FC; Bacon, Paul.
In: Annals of the Rheumatic Diseases, Vol. 63, No. 8, 01.01.2004, p. 974-81.Research output: Contribution to journal › Article
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry
AU - Farge, D
AU - Passweg, J
AU - van Laar, JM
AU - Marjanovic, Z
AU - Besenthal, C
AU - Finke, J
AU - Peter, HH
AU - Breedveld, FC
AU - Bacon, Paul
PY - 2004/1/1
Y1 - 2004/1/1
N2 - OBJECTIVE: To analyse the durability of the responses after haematopoietic stem cell transplantation (HSCT) for severe systemic sclerosis (SSc) and determine whether the high transplant related mortality (TRM) improved with experience. This EBMT/EULAR report describes the longer outcome of patients originally described in addition to newly recruited cases. METHODS: Only patients with SSc, treated by HSCT in European phase I-II studies from 1996 up to 2002, with more than 6 months of follow up were included. Transplant regimens were according to the international consensus statements. Repeated evaluations analysed complete, partial, or non-response and the probability of disease progression and survival after HSCT (Kaplan-Meier). RESULTS: Given as median (range). Among 57 patients aged 40 (9.1-68.7) years the skin scores improved at 6 (n = 37 patients), 12 (n = 30), 24 (n = 19), and 36 (n = 10) months after HSCT (p
AB - OBJECTIVE: To analyse the durability of the responses after haematopoietic stem cell transplantation (HSCT) for severe systemic sclerosis (SSc) and determine whether the high transplant related mortality (TRM) improved with experience. This EBMT/EULAR report describes the longer outcome of patients originally described in addition to newly recruited cases. METHODS: Only patients with SSc, treated by HSCT in European phase I-II studies from 1996 up to 2002, with more than 6 months of follow up were included. Transplant regimens were according to the international consensus statements. Repeated evaluations analysed complete, partial, or non-response and the probability of disease progression and survival after HSCT (Kaplan-Meier). RESULTS: Given as median (range). Among 57 patients aged 40 (9.1-68.7) years the skin scores improved at 6 (n = 37 patients), 12 (n = 30), 24 (n = 19), and 36 (n = 10) months after HSCT (p
UR - http://www.scopus.com/inward/record.url?scp=3242658935&partnerID=8YFLogxK
U2 - 10.1136/ard.2003.011205
DO - 10.1136/ard.2003.011205
M3 - Article
C2 - 15249325
VL - 63
SP - 974
EP - 981
JO - Annals of the Rheumatic Diseases
JF - Annals of the Rheumatic Diseases
SN - 0003-4967
IS - 8
ER -